Johnson & Johnson and Elan Corporation plc announces agreement for Alzheimer’s Immunotherapy Programme and Equity Investment
Thursday 02 July 2009
Johnson & Johnson “will acquire substantially all of the assets and rights of Elan related to its Alzheimer’s Immunotherapy Programme (AIP) in addition, Johnson & Johnson will invest $1 billion in Elan in exchange for newly issued American Depositary Receipts (ADRs) which will represent 18.4% of Elan’s outstanding ordinary shares.”
For more information on the AIP programme and details of the agreement please see the Johnson & Johnson website at: